Ann: Scientia Completes Cohort Dosing in Phase I/II UTI Trial, page-4

Highlights:
• Scientia Clinical Research complete cohort dosing ahead of schedule
• RECCE® 327 safe and well tolerated in male and female subjects at two faster
infusion rates of 2,500mg rates via I.V administration
• Independent Safety Committee to review cohort data – subject recruitment for
next cohort underway
SYDNEY Australia, 28 July 2023: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the
Company), the Company developing a new class of Synthetic Anti-infectives, is pleased to
report Scientia Clinical Research has successfully completed cohort dosing of both male
and female subjects in its Phase I/II UTI clinical trial evaluating RECCE® 327 (R327) at faster
infusion rates.
R327 was shown to be safe and well tolerated at two faster infusion rates of 2,500mg, with
an Independent Safety Committee reviewing complete cohort dosing data, expected to
recommend go ahead, with recruitment well underway.